Glaxo’s Drugs ’ Are More Beneficial than Chemotherapy

glaxoIt has been revealed in an up-to-date report that the current chemotherapy has failed in front of two experimental skin cancer drugs developed by GlaxoSmithKline.

The drugs named trametinib and dabrafenib are being said be more powerful as well as are being claimed to cause slight side-effects. It has been told by the team that the trial conducted to test the drugs has shown that the drugs allow patients to live for four to five months before the disease could worsen.

While according to the report, the current treatment recommended for treating melanoma, the deadliest form of skin cancer, is Roche's Zelboraf, or vemurafenib. But, the same after benefitting patients’ illness causes them to develop cutaneous squamous cell carcinoma or non-malignant lesion.

Meanwhile, it has been told that cancers are caused due to genetic changes in cells that activate various pathways like MEK. And BRAF-mutated melanomas particularly depend on MEK amplifying cancer's genetic signal.

The study involving participants with BRAF, a mutation in a gene, has proved beneficial over the Roche drug. It is being said that the drugs cause eye problems or skin rash in 6 to 7% of patients as side-effects but is much effective as well.